Results 211 to 220 of about 648,282 (342)

Factors associated with placebo response rate in randomized controlled trials of antiseizure medications for focal epilepsy. [PDF]

Epilepsia
Kerr WT, Suprun M, Kok N, Reddy AS, McFarlane KN, Kwan P, Somerville E, Bagiella E, French JA.   +8 more
europepmc   +1 more source

Placebo response varies between different types of sham acupuncture: A randomized double-blind trial in neck pain patients. [PDF]

Eur J Pain, 2022
Zeng D, Yan X, Deng H, Li J, Xiao J, Yuan J, Huang J, Xu N, Fu W, Liu J.   +9 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Herbal placebo response in clinical trials on irritable bowel syndrome: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Huang K, Lv M, Zheng T, Wang F, Tang X, Lv L.   +5 more
europepmc   +1 more source

Comparison of haemodynamic responses to direct laryngoscopy and intubation with gabapentin versus placebo

, 2020
MHanumantha Rao, PeyyetyJanaki Subhadra, Gururaj Nagaraj   +2 more
openalex   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. [PDF]

Int J Neuropsychopharmacol, 2022
Bloomfield-Clagett B, Ballard ED, Greenstein DK, Wilkinson ST, Grunebaum MF, Murrough JW, Mathew SJ, Phillips JL, Fava M, Sanacora G, Zarate CA.   +10 more
europepmc   +1 more source

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Inpatient's, therapist's and staff's expectations regarding treatment and their effects on placebo response in the psychiatric ward - results from an add-on oxytocin RCT. [PDF]

Psychopharmacology (Berl)
Nitzan U, Grossman-Girron A, Sedoff O, Maoz H, Arad O, Tilbor E, Dror C, Bitan DT.   +7 more
europepmc   +1 more source